Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Biophys J ; 120(14): 2848-2858, 2021 07 20.
Article in English | MEDLINE | ID: covidwho-1607443

ABSTRACT

Large-scale conformational transitions in the spike protein S2 domain are required during host-cell infection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Although conventional molecular dynamics simulations have been extensively used to study therapeutic targets of SARS-CoV-2, it is still challenging to gain molecular insight into the key conformational changes because of the size of the spike protein and the long timescale required to capture these transitions. In this work, we have developed an efficient simulation protocol that leverages many short simulations, a dynamic selection algorithm, and Markov state models to interrogate the structural changes of the S2 domain. We discovered that the conformational flexibility of the dynamic region upstream of the fusion peptide in S2 is coupled to the proteolytic cleavage state of the spike protein. These results suggest that opening of the fusion peptide likely occurs on a submicrosecond timescale after cleavage at the S2' site. Building on the structural and dynamical information gained to date about S2 domain dynamics, we provide proof of principle that a small molecule bound to a seam neighboring the fusion peptide can slow the opening of the fusion peptide, leading to a new inhibition strategy for experiments to confirm. In aggregate, these results will aid the development of drug cocktails to inhibit infections caused by SARS-CoV-2 and other coronaviruses.


Subject(s)
COVID-19 , Spike Glycoprotein, Coronavirus , Humans , Peptides , SARS-CoV-2 , Virus Internalization
2.
Sci Rep ; 11(1): 16307, 2021 08 11.
Article in English | MEDLINE | ID: covidwho-1354117

ABSTRACT

Structure-based drug design targeting the SARS-CoV-2 virus has been greatly facilitated by available virus-related protein structures. However, there is an urgent need for effective, safe small-molecule drugs to control the spread of the virus and variants. While many efforts are devoted to searching for compounds that selectively target individual proteins, we investigated the potential interactions between eight proteins related to SARS-CoV-2 and more than 600 compounds from a traditional Chinese medicine which has proven effective at treating the viral infection. Our original ensemble docking and cooperative docking approaches, followed by a total of over 16-micorsecond molecular simulations, have identified at least 9 compounds that may generally bind to key SARS-CoV-2 proteins. Further, we found evidence that some of these compounds can simultaneously bind to the same target, potentially leading to cooperative inhibition to SARS-CoV-2 proteins like the Spike protein and the RNA-dependent RNA polymerase. These results not only present a useful computational methodology to systematically assess the anti-viral potential of small molecules, but also point out a new avenue to seek cooperative compounds toward cocktail therapeutics to target more SARS-CoV-2-related proteins.


Subject(s)
Antiviral Agents/pharmacology , Drug Evaluation, Preclinical , Drugs, Chinese Herbal/pharmacology , Medicine, Chinese Traditional , SARS-CoV-2/drug effects , Viral Proteins/metabolism , Angiotensin-Converting Enzyme 2/metabolism , Animals , Antiviral Agents/chemistry , Antiviral Agents/metabolism , Cats , Computational Biology , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/metabolism , Flavonoids/metabolism , Humans , Molecular Dynamics Simulation , Protein Binding , RNA-Dependent RNA Polymerase/metabolism , Spike Glycoprotein, Coronavirus/metabolism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL